tbuckley/cabot-search huggingface dataset:
EPID-21ONE-YEAR INSTITUTIONAL REPORT OF THE FIRST CANADIAN ADULT NF1 MULTIDISCIPLINARY CLINIC, REPORTED IN THE CONTEXT OF SYSTEMATICALLY-IDENTIFIED EXPERIENCES OF PREVIOUSLY ESTABLISHED CENTERS
Authors: Alireza Mansouri, Saber Ghadakzadeh, Talha Maqbool, Carolina Barnett, Paul Kongkham, Vera Bril, Gelareh Zadeh
Journal: Neuro-Oncology (2015)

BACKGROUND: Neurofibromatosis type 1 (NF1) is among the most common single-gene disorders. These patients are afflicted by a myriad of biopsychosocial challenges. A multidisciplinary approach to the diagnosis and management of patients with NF1 is necessary. A dearth of multidisciplinary clinics for adults is a palpable limitation. OBJECTIVES: To report our one-year institutional experience with the first Canadian multidisciplinary adult NF1 clinic at the University Health Network (UHN), in the context of other systematically-identified published experiences by established clinics worldwide. METHODS: The UHN NF1 clinic consists of 2 neurosurgeons and 2 neurologists with a permanent presence in the clinic. Clinics were initially once-monthly but have recently been increased to once-weekly. A modified version of the NF Patient Registry Initiative questionnaire was adapted for use as the patient intake questionnaire for new UHN NF1 patients. The MEDLINE, EMBASE, and CENTRAL electronic databases were systematically searched to identify publications pertaining to the experience of multidisciplinary adult NF1 clinics. Data on structure of clinics, patient epidemiology, along with management and follow-up strategies were recorded. RESULTS: Six articles were identified (range of 19-177 unique patients seen); two pertained to only adults and 5 pertained to a mixed population. The majority of clinics involved neurologists and medical geneticists as permanent members. The UHN NF1 clinic was the first in Canada and the first to involve neurosurgeons as permanent members. Sixty-six (of 86) unique patients completed the intake questionnaire. The demographic and clinical data from this Canadian population is mostly consistent with previous reports with some exceptions. Only 9% of patients were referred from a pediatric NF1 center. CONCLUSIONS: Our data offers valuable information to healthcare professionals and adult patients affected by NF1. Awareness of current limitations and areas of improvement would be of utility for establishing additional highly-necessary adult centers.
Just a Cut
Authors: Eileen P. Scully, Brandon E. Earp, Amy L. Miller, Joseph Loscalzo
Journal: New England Journal of Medicine (2016)

A 51-year-old surgeon lacerated his left ring finger near the volar distal interphalangeal joint with a fillet knife while cleaning fish after a late summer day of fishing in coastal New England seawaters. Twelve hours later, he awoke with throbbing pain in his fingertip.
Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML
Authors: Wontak Kim, Brigham L. Bahr, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, Clifford J. Whatcott, Adam Siddiqui-Jain, Steven Weitman, David J. Bearss, Steven L. Warner
Journal: Blood (2015)
Documentation of Idiotypic Cascade after Lym-1 Radioimmunotherapy in a Patient with Non-Hodgkin’s Lymphoma
Authors: Bonnie M. Bradt, Sally J. DeNardo, Gary R. Mirick, Gerald L. DeNardo
Journal: Clinical Cancer Research (2003)

Purpose: The purpose of this study was to examine idiotypic cascade mechanisms in the plasma of a prolonged survivor patient with aggressive non-Hodgkin’s lymphoma (NHL). It is a follow-up to previously published seminal studies by this laboratory showing survival benefit associated with radioimmunotherapy in NHL patients. Immunoglobulin from the patient’s plasma was purified, characterized, and shown to possess the activities expected of idiotypic antibodies.

Experimental Design: Plasma from a NHL patient treated with Lym-1 was precipitated with ammonium sulfate and octanoic acid, followed by immunoadsorbant chromatography with solid phase Lym-1 monoclonal antibody to purify Ab2. The last purification step involved the binding of Ab3 to glutaraldehyde-fixed Raji cells, followed by acid elution of Ab3. Proteins were quantified and characterized. Antibody-dependent cellular cytotoxicity activity was determined using a standard 51Cr release assay.

Results: Purified immunoglobulin populations exhibited the characteristics of Ab2β and Ab3 antibodies. Both showed ability to compete with the binding of Lym-1 to its tumor cell target, and Ab3 showed ability to induce antibody-dependent cellular cytotoxicity.

Conclusions: This study offers direct evidence for initiation of a multilevel idiotypic cascade in a patient undergoing passive monoclonal antibody therapy for NHL. The patient’s prolonged disease-free survival may, thus, be understood in the context of the generation of endogenous, self-perpetuating tumor-specific antibodies.
Anti-Myeloma Response to Bortezomib Is Associated with Increased Osteoblast Activity and Bone Formation in Primary Myelomatous SCID-rab Mice.
Authors: Shmuel Yaccoby, Wen Ling, Rinku Saha, Bart Barlogie, Guido Tricot, Maurizio Zangari
Journal: Blood (2005)
Abstract 352: Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
Authors: Yan Gao, Rosemary Foster, Francis J. Hornicek, Mansoor M. Amiji, Zhenfeng Duan
Journal: Cancer Research (2015)

Abstract Purpose: The clinical significance of Cluster of differentiation 44 (CD44) remains controversial in human ovarian cancer. The aim of this study is to evaluate the clinical significance of CD44 expression by using a unique tissue microarray, and then to determine the biological functions of CD44 in ovarian cancer. Experimental Design: A unique ovarian cancer tissue microarray (TMA) was constructed with paired primary, metastatic, and recurrent tumor tissues from 26 individual patients. CD44 expression in TMA was assessed by immunohistochemistry. Western blotting and Immunofluorescence assay determined the expression of CD44 and/or P-glycoprotein (Pgp) in ovarian cancer cell lines and the tumor tissues of a paclitaxel treated ovarian cancer xenograft mouse model. MTT assay, wound healing assay, and matrigel invasion assay were utilized to assess the proliferation, drug sensitivity, and migration/invasion ability, respectively. Results: Both the metastatic and recurrent ovarian cancer tissues expressed higher level of CD44 than the patient-matched primary tumor. A significant association has been shown between CD44 expression and both the disease free survival and overall survival. A strong increase of CD44 was found in the tumor recurrence of mouse model. Finally, when CD44 was knocked down, proliferation, migration/invasion activity, and spheroid formation were significantly suppressed, while drug sensitivity was enhanced. Conclusions: Up-regulation of CD44 represents a crucial event in the development of metastasis, recurrence, and drug resistance to current treatments in ovarian cancer. Developing strategies to target CD44 may prevent metastasis, recurrence, and drug resistance in ovarian cancer. Citation Format: Yan Gao, Rosemary Foster, Francis J. Hornicek, Mansoor M. Amiji, Zhenfeng Duan. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 352. doi:10.1158/1538-7445.AM2015-352
Postremission Therapy in Adult Acute Myeloid Leukemia (AML): A Randomized Comparison of Intensified Consolidation Therapy without Maintenance Therapy Against Conventional Consolidation with Maintenance Therapy -JALSG AML-97 Trial-.
Authors: Shuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, Fumiharu Yagasaki, Kinuko Mitani, Shin Matsuda, Yuji Kishimoto, Yasushi Miyazaki, Norio Asou, Yoshiaki Ogawa, Sumihisa Honda, Ryuzo Ohno
Journal: Blood (2004)
Thermothelomyces thermophila human infections
Authors: C. Nourrisson, D. Garcia-Hermoso, F. Morio, C. Kauffmann-Lacroix, N. Berrette, J. Bonhomme, P. Poirier, O. Lortholary, F. Cazenave Roblot, D. Hoinard, E. Launay, R.A. Lavergne, C. Le Naourès Méar, P. Penn, B. Rammaert, K. Sitbon, M. Vidal-Roux
Journal: Clinical Microbiology and Infection (2016)
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4
Authors: Alexander GG Turpie, Kenneth A. Bauer, Bruce Davidson, Michael Gent, Louis Kwong, Michael Rud Lassen, Fred Cushner, Paul Lotke, Scott D. Berkowitz, Tiemo Joerg Bandel, Frank Misselwitz, William Fisher
Journal: Blood (2008)
Novel Link between PI 3′ Kinase/p38 Map Kinase Pathway in Dasatinib (BMS354825) Mediated Effect in BCR-ABL Expressing Cells.
Authors: Crystal Lumby, VeerPal Singh, Shrisha Reddy, Sue Sivess-Franks, Jonathan Dowell, Amit Verma, Simrit Parmar
Journal: Blood (2007)
Superior Outcome Using Cyclosporin A Alone Versus Cyclosporin A Plus Methotrexate for Post-Transplant Immunosuppression In Children with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Authors: Bernd Gruhn, Melissa Weiß, Ilona Wolff, Felix Zintl, James F. Beck
Journal: Blood (2010)
Whole Exome Sequencing of Flow Purified Tumour Cells Reveals Recurrently Mutated Genes and Pathways in Adult T-Cell Lymphoma/Leukaemia (ATLL)
Authors: Richard Dillon, Lucy Cook, Alka Saxena, Rosamond Nuamah, Ghazala Mirza, Amie Jaye, Michael Simpson, Sean Whittaker, Charles R. M. Bangham, Graham P. Taylor, Paul Fields
Journal: Blood (2015)
Guanine nucleotide exchange factor RABGEF1 regulates keratinocyte-intrinsic signaling to maintain skin homeostasis
Authors: Thomas Marichal, Nicolas Gaudenzio, Sophie El Abbas, Riccardo Sibilano, Oliwia Zurek, Philipp Starkl, Laurent L. Reber, Dimitri Pirottin, Jinah Kim, Pierre Chambon, Axel Roers, Nadine Antoine, Yuko Kawakami, Toshiaki Kawakami, Fabrice Bureau, See-Ying Tam, Mindy Tsai, Stephen J. Galli
Journal: Journal of Clinical Investigation (2016)

Epidermal keratinocytes form a structural and immune barrier that is essential for skin homeostasis. However, the mechanisms that regulate epidermal barrier function are incompletely understood. Here we have found that keratinocyte-specific deletion of the gene encoding RAB guanine nucleotide exchange factor 1 (RABGEF1, also known as RABEX-5) severely impairs epidermal barrier function in mice and induces an allergic cutaneous and systemic phenotype. RABGEF1-deficient keratinocytes exhibited aberrant activation of the intrinsic IL-1R/MYD88/NF-κB signaling pathway and MYD88-dependent abnormalities in expression of structural proteins that contribute to skin barrier function. Moreover, ablation of MYD88 signaling in RABGEF1-deficient keratinocytes or deletion of Il1r1 restored skin homeostasis and prevented development of skin inflammation. We further demonstrated that epidermal RABGEF1 expression is reduced in skin lesions of humans diagnosed with either atopic dermatitis or allergic contact dermatitis as well as in an inducible mouse model of allergic dermatitis. Our findings reveal a key role for RABGEF1 in dampening keratinocyte-intrinsic MYD88 signaling and sustaining epidermal barrier function in mice, and suggest that dysregulation of RABGEF1 expression may contribute to epidermal barrier dysfunction in allergic skin disorders in mice and humans. Thus, RABGEF1-mediated regulation of IL-1R/MYD88 signaling might represent a potential therapeutic target.
Global Activation of Coagulation Is the Initiating Event of Acute Coagulopathy of Trauma As Modeled By Hemorrhage and Lower Body Negative Pressure in Baboons
Authors: Heather F Pidcoke, Chriselda G Fedyk, Robbie K Montgomery, Carmen Hinojosa-Laborde, Victor A Convertino, Robert E Shade, Andrew P Cap
Journal: Blood (2014)
Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis
Authors: Timothy Lawes, José-María Lopez-Lozano, Cesar A Nebot, Gillian Macartney, Rashmi Subbarao-Sharma, Karen D Wares, Carolyn Sinclair, Ian M Gould
Journal: The Lancet Infectious Diseases (2016)
Unusual Locations for Lymphomas
Authors: Hamid Mansouri, Taeb Kebdani, Khalid Hassouni, Brahim El Gueddari
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.11.2959 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11387369 Unusual Locations for Lymphomas Case 1. Intermediate-Grade Lymphoma of the Cervix Hamid MansourixHamid MansouriSearch for articles by this author , Taeb KebdanixTaeb KebdaniSearch for articles by this author , Khalid HassounixKhalid HassouniSearch for articles by this author , Brahim El GueddarixBrahim El GueddariSearch for articles by this author Show More National Cancer Institut, Rabat University of Medicine, Rabat, Morocco, Copyright © 2001 American Society of Clinical Oncology https://doi.org/10.1200/JCO.2001.19.11.2959 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Quantifying effect of age on the risk of revision following hip and knee replacement using life-time risk estimates: an analysis of 117,438 total joint replacements from the UK Clinical Practice Research Datalink
Authors: L E Bayliss, D Culliford, A P Monk, S Glyn-Jones, D Prieto Alhambra, A D Judge, C Cooper, A J Carr, N Arden, D Beard, A J Price
Journal: The Lancet (2017)
Screening for breast cancer: U.S. preventive services task force recommendation statement
Authors: Ned Calonge, Diana B. Petitti, Thomas G. DeWitt, Allen J. Dietrich, Kimberly D. Gregory, David Grossman, George Isham, Michael L. LeFevre, Rosanne M. Leipzig, Lucy Nelle Marion, Bernadette Melnyk, Virginia A. Moyer, Judith K. Ockene, George F. Sawaya, J. Sanford Schwartz, Timothy Wilt
Journal: Annals of Internal Medicine (2009)
Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM)
Authors: Jianxiang Wang, Xiaojun Huang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang
Journal: Blood (2011)
Identifying Immunogenetic Features That Distinguish Immune Mediated, Immunosuppression-Sensitive Disease in Aplastic Anemia (AA)
Authors: Manuel G. Afable, Theresa Guo, Bartlomiej P Przychodzen, Lisa Rybicki, Michael J. Clemente, Andres Jerez, Holleh D Husseinzadeh, Edward P Evans, Alan E. Lichtin, Aleksandra Wodnar-Filipowicz, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2012)
In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).
Authors: Noopur Raje, Shaji Kumar, Teru Hideshima, Kenji Ishitsuka, Aldo Roccaro, Hiroshi Yasui, Makoto Hamasaki, Norihiko Shiraishi, Dharminder Chauhan, Nikhil C. Munshi, Simon R. Green, Kenneth C. Anderson
Journal: Blood (2004)
Changing global policy to deliver safe, equitable, and affordable care for women’s cancers
Authors: Ophira Ginsburg, Rajan Badwe, Peter Boyle, Gemma Derricks, Anna Dare, Tim Evans, Alexandru Eniu, Jorge Jimenez, Tezer Kutluk, Gilberto Lopes, Sulma I Mohammed, You-Lin Qiao, Sabina Faiz Rashid, Diane Summers, Diana Sarfati, Marleen Temmerman, Edward L Trimble, Aasim I Padela, Ajay Aggarwal, Richard Sullivan
Journal: The Lancet (2016)
Initial safety and efficacy results of erlotinib in previously treated patients with advanced non-small cell lung cancer
Authors: S. Zhou, C. Zhou, L. Yan, Q. Xu, J. Xu
Journal: Journal of Clinical Oncology (2007)

18183 Background: Erlotinib is an orally available selective HER1/EGFR tyrosine kinase inhibitor. In the BR.21 trial, erlotinib significantly improved survival and quality of life in non-small cell lung cancer(NSCLC) patients (pts). The study evaluated the initial efficacy and safety of erlotinib in previously treated advanced or metastatic NSCLC patients in Shanghai, China. Methods: Eligibility criteria included stage IIIb/IV or recurrent NSCLC pts who failed from prior chemotherapy, PS = 0–2, weight loss less than 5%, and no urgent symptoms. Pts received oral erlotinib 150 mg po/day until objective or symptomatic progression. Results: 50 pts were enrolled from Oct 1 to Sept 30. Demographics: M 68%/F 32%; median age 55 y [range 28–68]; stage IV 86%; PS 0/1/2:2 (4%)/44 (88%)/4 (8%); adenocarcinoma/non-adenocarcinoma 39 (78%)/11 (22%); smoking status: 26 (52%) /no 24 (48%). The major toxicity was rash: 48 (96%), 10 (20%) of them are grade 3/4; other toxicity included grade 1/2 diahhrea: 5 (10%); grade 1/2 liver dysfunction: 4 (8%); grade 2 leucocytopenia: 2 (4%); grade 1 thrombocytopenia: 1(2%); fatigue and dyspnea. 3 patients discontinued for dyspnea, pneumonitis and fatigue respectively. No pts had pulmonary fibrosis and dose reduction. 47 pts were followed long enough for efficacy evaluation, which indentified 18 (38%) with PR, 21 (45%) with SD, 8 (17%) with PD. Subgroup analysis showed the resposes to erlotinib have no relation with gender, age, smoking status, performance status, histology and stages, however, significant difference existed in the subgroup patients with severe rash and less symptoms such as dyspnea and fatigue ( Table 1 ). Conclusions: Erlotinib is active and well tolerated in patients with advanced NSCLC failed to previously chemotherapy. Preliminary results suggest patients with severe rash, less dyspnea and fatigue are accociated with better response. The study in ongoing. Table 1 Response of erlotinib in advanced treated NSCLC pts. * P values less than 0.05. [Table: see text] No significant financial relationships to disclose.
Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial
Authors: Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe
Journal: Blood (2015)
Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors
Authors: Rajendar K. Mittapalli, Chris E. Adkins, Kaci. A. Bohn, Afroz S. Mohammad, Julie A. Lockman, Paul R. Lockman
Journal: Cancer Research (2016)

Abstract Tumors residing in the central nervous system (CNS) compromise the blood–brain barrier (BBB) via increased vascular permeability, with the magnitude of changes dependent on the tumor type and location. Current studies determine penetrability of a cancer therapeutic by administering progressively larger molecules until cutoff is observed where little to no tumor accumulation occurs. However, decades-old experimental work and mathematical modeling document methods to calculate both the size of the vascular opening (pore) with solute permeability values. In this study, we updated this classic mathematical modeling approach with quantitative fluorescence microscopy in two preclinical tumor models, allowing simultaneous administration of multiple sized tracers to determine vascular permeability at a resolution of nearly one micron. We observed that three molecules ranging from 100 Da to 70 kDa permeated into a preclinical glioblastoma model at rates proportional to their diffusion in water. This suggests the solutes freely diffused from blood to glioma across vascular pores without steric restriction, which calculates to a pore size of &amp;gt;140 nm in diameter. In contrast, the calculated pore size of a brain metastasis of breast cancer was approximately 10-fold smaller than glioma vasculature. This difference explains why antibodies are effective against glioblastoma but generally fail in brain metastases of breast cancer. On the basis of our observations, we hypothesize that trastuzumab most likely fails in the treatment of brain metastases of breast cancer because of poor CNS penetration, while the similar sized antibody bevacizumab is effective in the same tumor type not because it penetrates the CNS degree better, but because it scavenges VEGF in the vascular compartment, which reduces edema and permeation. Cancer Res; 77(2); 238–46. ©2016 AACR.
A phase III clinical trial of intra-arterial yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma.
Authors: Maria Angela Karpf
Journal: Journal of Clinical Oncology (2015)

477 Background: Primary liver cancer is the fifth most commonly diagnosed cancer in men and eight most common in women. Currently, sorafenib is SOC treatment for pts with advanced hepatocellular carcinoma (HCC); however, it is associated with only modest improvement in median survival compared with best supportive care. Sorafenib is associated with significant toxicity. Yttrium 90 glass microspheres (TheraSphere; 90 Y) have an HDE in the US for use in radiation treatment or as a neoadjuvant to surgery or transplantation in pts with unresectable HCC who can have placement of appropriately positioned hepatic arterial catheters. The purpose of this study is to evaluate treatment with 90 Y in HCC pts who will then receive SOC sorafenib and to compare survival outcomes with those of pts receiving only sorafenib. The primary objective is to evaluate 90 Y in pts with unresectable HCC where SOC sorafenib is planned. Methods: This Phase 3, open-label, multi-center, randomized study will evaluate 90 Y treatment in ~390 pts with unresectable HCC. Eligible pts (where SOC sorafenib therapy is already planned) will be randomized 1:1 to control and treatment. Control patients will receive SOC sorafenib according to label. The treatment group will receive 90 Y prior to SOC sorafenib. Primary outcome is overall survival from time of randomization. Secondary endpoints include time to progression/untreatable progression/symptomatic progression, tumor response, quality of life, and adverse events. Sorafenib pts will have study visits every 8 wks for as long as the patient remains in study. Pts randomized to 90 Y will have pre-treatment evaluations and treatment to the first lobe during wks 3-4; patients with bilobar disease will have pre-treatment evaluations and treatment to the second lobe during wks 5-8. After 90 Y treatment, study visits will occur every 8 wks as long as the pts remain in study. Follow-up visits will occur every 8 wks from randomization until disease progression. Results: This study is ongoing. Conclusions: This Phase 3 study will evaluate use of 90 Y in advanced HCC patients given its potential to enhance survival with less toxicity than the current SOC. Clinical trial information: NCT01556490.